DNAprint Genomics (DNAG)

[ann441j]

On Statinome:

"STATINOME™ - This test is currently being developed for the cardiac drug market, and is expected to enable a classification of patients as adverse responders or normal responders to a class of drugs known as “statins”. Statins are drugs used to treat patients who are at increased risk of heart disease. Once perfected, we believe STATINOME™ should be able to improve the rewards associated with taking statins by reducing the risks associated with adverse response sometimes seen in minority of patients.

In addition to OVANOME™, we have initiated several studies for cancer drugs with the H. Lee Moffitt Cancer Research Center in Tampa, FL (colon cancer, post-operative nausea and vomiting in cancer patients undergoing surgery and multiple Myeloma). We hope to develop the additional expertise to help us better guide the clinical development of compounds that we will be acquiring for our own drug development pipeline."

Good luck to all!

Ann